603222.SH
济民健康
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 8.06
−1.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 668.0M | 686.0M | 775.7M | 894.5M | 837.2M |
| Cost of Revenue | 468.3M | 473.0M | 486.3M | 515.0M | 449.7M |
| Gross Profit | 199.8M | 213.0M | 289.5M | 379.6M | 387.5M |
| Operating Expenses | |||||
| R&D Expense | 45.3M | 47.9M | 41.6M | 28.9M | 28.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 113.1M | 111.5M | 118.3M | 109.3M | 100.2M |
| Selling & Marketing Expense | 135.6M | 139.5M | 162.7M | 184.3M | 158.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 332.2M | 336.0M | 352.5M | 353.0M | 320.8M |
| Cost and Expenses | 800.5M | 809.0M | 838.8M | 868.0M | 770.6M |
| Operating Income (EBIT) | (214.8M) | (207.0M) | (63.6M) | (43.8M) | 46.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (241.8M) | (233.9M) | (66.5M) | (49.2M) | 42.9M |
| Income Tax Expense | 17.6M | 12.9M | (10.3M) | 41.6K | 16.8M |
| Bottom Line | |||||
| Net Income | (257.9M) | (245.6M) | (59.7M) | (65.5M) | 34.5M |
| Earnings from Cont. Ops | (259.4M) | (246.8M) | (56.1M) | (49.2M) | 26.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (257.9M) | (245.6M) | (59.7M) | (65.5M) | 34.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.49) | (CN¥0.47) | (CN¥0.11) | (CN¥0.12) | CN¥0.07 |
| Diluted EPS | (CN¥0.49) | (CN¥0.47) | (CN¥0.11) | (CN¥0.12) | CN¥0.07 |
| Revenue Per Share | CN¥1.29 | CN¥1.31 | CN¥1.43 | CN¥1.64 | CN¥1.70 |
| Shares | |||||
| Basic Shares Outstanding | 518.4M | 522.5M | 542.8M | 545.7M | 492.2M |
| Diluted Shares Outstanding | 518.4M | 522.5M | 542.8M | 545.7M | 492.2M |
| Profitability Metrics | |||||
| EBITDA | — | (99.2M) | 41.2M | 52.5M | 124.0M |
| D&A | — | 107.8M | 104.8M | 96.3M | 78.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026